Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis
Interventions
DRUG

cyclosporine A 0.05% eye drops

"Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months."

Trial Locations (1)

13001

Farwanyia Hospital, Al Farwānīyah

All Listed Sponsors
lead

Farwaniya Hospital

OTHER_GOV

NCT05720715 - Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis | Biotech Hunter | Biotech Hunter